Reig Jofre Group
European pharmaceutical company with GMP aseptic sterile manufacturing and commercial vial fill–finish for injectables and vaccines. R&D activities include biologics and advanced therapies, biofabrication scale‑up (3D‑bioprinted autologous skin substitutes), molecular in vitro diagnostics, and dermatology product development. The company also pilots AI-enabled digital rehabilitation services and maintains international commercial operations including a newly opened subsidiary in the Czech Republic. Public reporting sources cited consolidated 2023 sales of approximately €316 million with an EBITDA of €35 million, and later reporting indicated a record net profit exceeding €10 million.
Industries
Nr. of Employees
Very Large (1000+)
Reig Jofre Group
Barcelona, Catalonia, Spain, Europe
Products
Osteoarticular and dermatology prescription medicines
Prescription medicines and specialty pharmacare products for musculoskeletal and dermatological indications distributed in multiple European markets via subsidiaries and partners.
Consumer healthcare and OTC products
Over‑the‑counter consumer health and wellness products across categories such as weight control, energy, stress and sleep, intended for phased commercial rollout in new subsidiaries.
Dermatology topical skincare range for acne‑prone skin
Pharmacy-distributed topical skincare products for acne-prone skin developed using biotechnologically derived plant actives; clinical studies reported and planned rollout across European subsidiaries.
Molecular in vitro diagnostic for endometrial cancer (commercialized)
Commercialized molecular diagnostic test intended to provide molecular classification from aspirate samples with rapid laboratory turnaround for clinical laboratories and hospitals.
Biofabricated autologous skin substitutes (in development)
3D‑bioprinted autologous skin substitutes designed for burns and complex wounds; development includes scale‑up plans and planned clinical evaluation in pediatric patients.
Osteoarticular and dermatology prescription medicines
Prescription medicines and specialty pharmacare products for musculoskeletal and dermatological indications distributed in multiple European markets via subsidiaries and partners.
Consumer healthcare and OTC products
Over‑the‑counter consumer health and wellness products across categories such as weight control, energy, stress and sleep, intended for phased commercial rollout in new subsidiaries.
Dermatology topical skincare range for acne‑prone skin
Pharmacy-distributed topical skincare products for acne-prone skin developed using biotechnologically derived plant actives; clinical studies reported and planned rollout across European subsidiaries.
Molecular in vitro diagnostic for endometrial cancer (commercialized)
Commercialized molecular diagnostic test intended to provide molecular classification from aspirate samples with rapid laboratory turnaround for clinical laboratories and hospitals.
Biofabricated autologous skin substitutes (in development)
3D‑bioprinted autologous skin substitutes designed for burns and complex wounds; development includes scale‑up plans and planned clinical evaluation in pediatric patients.
Services
Contract manufacturing: aseptic fill–finish and injectable production
On‑site GMP aseptic vial filling/finishing and injectable manufacturing services, including handling and dosing of frozen bulk biological material and commercial‑scale production capabilities.
Digital rehabilitation service deployment
Validation and market piloting of AI‑based remote physiotherapy platforms for musculoskeletal care, delivered via partnerships or platform licensing.
Consortia and cluster collaboration
Participation in regional cluster activities, industry consortia and public–private partnerships to coordinate collaborative R&D, manufacturing capacity planning and regional innovation strategies.
Contract manufacturing: aseptic fill–finish and injectable production
On‑site GMP aseptic vial filling/finishing and injectable manufacturing services, including handling and dosing of frozen bulk biological material and commercial‑scale production capabilities.
Digital rehabilitation service deployment
Validation and market piloting of AI‑based remote physiotherapy platforms for musculoskeletal care, delivered via partnerships or platform licensing.
Consortia and cluster collaboration
Participation in regional cluster activities, industry consortia and public–private partnerships to coordinate collaborative R&D, manufacturing capacity planning and regional innovation strategies.
Expertise Areas
- Aseptic fill–finish and sterile injectable manufacturing
- Biopharmaceutical R&D and advanced therapies
- Biofabrication and 3D bioprinting scale-up
- Clinical trial design and translational validation
Key Technologies
- Aseptic vial fill–finish processes
- Cold‑chain and frozen bulk handling
- 3D bioprinting for tissue substitutes
- Biotechnological plant‑derived active ingredients